Studies have shown that STMN1 mediates resistance to anti-mitotic chemo-drugs in tumor cells [5] and its inhibition enhances sensitivity to paclitaxel/docetaxel in osteosarcoma [26], gastric cancer [27] and PCa [28]. Here, STMN1 is linked to posterior cortical atrophy.